Pharma Gets 340B Appeals Court Victory But More Decisions Are Pending; Will Congress Step In?
Executive Summary
Third Circuit is first of three federal appeals courts to issue a decision in multiple lawsuits over drug companies’ 340B contract pharmacy restrictions, which have led to conflicting lower court rulings on whether such restrictions are unlawful.
You may also be interested in...
340B Program At ‘Critical Inflection Point,’ Oversight Agency Head Tells Providers
The head of the federal agency overseeing the 340B drug discount program offers unusually direct calls for legislative action during the safety net provider association winter conference. But is action likely in Congress any time soon?
Senate 340B Draft Bill May Add Contract Pharmacy Limits, Has Placeholder For Patient Definition
A bipartisan group of senators issues a request for information to fill gaps in their wide-ranging draft bill on the 340B program. The legislation covers the participation of contract pharmacies, eligibility of "child sites," claims transparency, abuses by pharmacy benefit managers, and a third party claims clearinghouse that would monitor for duplicate discounts.
340B Court Decision Threatens To Expand Patient Eligibility; Can Pharmacy Restrictions Counter Program Growth?
Court ruling in litigation brought against the US government by Genesis Healthcare may elicit competing reactions among stakeholders but is expected to stir up the 340B market.